Tim Lugo
Stock Analyst at William Blair
(0.59)
# 3,729
Out of 4,818 analysts
28
Total ratings
35.29%
Success rate
-21.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $1.09 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $62.02 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.37 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $26.95 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $3.56 | +1,023.60% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $7.27 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $176.95 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $0.33 | - | 3 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.20 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $16.68 | - | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.40 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.17 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $7.64 | +712.05% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.87 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.65 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.43 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.32 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $21.48 | +114.15% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.09
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $62.02
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.37
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $26.95
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $3.56
Upside: +1,023.60%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.27
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $176.95
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.33
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.20
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $16.68
Upside: -
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.40
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.17
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $7.64
Upside: +712.05%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.87
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $37.65
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.43
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.32
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $21.48
Upside: +114.15%